Assembly Biosciences Expands ABI-6250 Clinical Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 22 2026
0mins
Assembly Biosciences announced plans to expand the clinical development of ABI-6250, its oral entry inhibitor candidate for chronic hepatitis delta virus infection, into primary biliary cholangitis and primary sclerosing cholangitis, broadening the program into cholestatic liver diseases. "We are excited to expand the ABI-6250 program into PBC and PSC, where there remains significant unmet medical need despite existing PBC therapies, and in the case of PSC, no approved treatments," said Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio. "The NTCP receptor plays an integral role in both HDV entry and bile acid transport into liver cells, making it a compelling target across multiple liver diseases. We believe ABI-6250 has the potential to address key drivers of disease pathology in these conditions and look forward to advancing clinical evaluation in these populations."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ASMB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ASMB
Wall Street analysts forecast ASMB stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 24.490
Low
39.00
Averages
43.00
High
50.00
Current: 24.490
Low
39.00
Averages
43.00
High
50.00
About ASMB
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Assembly Biosciences Prices Underwritten Offering at $2.65 per Share
- Offering Size: Assembly Biosciences has priced its offering of 3,358,602 shares of common stock at $2.65 per share, aiming to raise approximately $100 million to support the development of its pipeline candidates and for general corporate purposes.
- Pre-Funded Warrants: The company is also offering certain investors pre-funded warrants to purchase up to 415,000 shares at an exercise price of $0.001 per share, which enhances investor flexibility and participation.
- Underwriter Option: Assembly has granted underwriters a 30-day option to purchase an additional 566,040 shares at the same offering price, potentially providing additional financial support and enhancing the company's liquidity.
- Closing Date: The offering is expected to close on or before May 26, 2026, marking a proactive approach in the capital markets to secure funding for future research and operational needs.
See More
Assembly Biosciences Prices 3.36M Share Offering at $26.50
- Offering Size: Assembly Biosciences announced an underwritten offering of approximately 3.36 million common shares at $26.50 per share, expecting to generate about $100 million in gross proceeds before expenses, thereby strengthening its financial position for future growth.
- Investor Participation: The offering attracted participation from both new and existing investors, including Gilead Sciences and Commodore Capital, reflecting market confidence in the company's potential and further solidifying its investor base in the biopharmaceutical sector.
- Additional Option: The company granted underwriters a 30-day option to purchase up to an additional 566,040 shares, enhancing the offering's flexibility and market responsiveness, which could potentially increase the total financing amount.
- Use of Proceeds: The net proceeds from the offering will be used to fund clinical development of pipeline candidates and for general corporate purposes, indicating the company's commitment to advancing its R&D efforts and optimizing resource allocation for long-term growth.
See More
Assembly Biosciences Prices $100 Million Underwritten Offering
- Offering Size: Assembly Biosciences announced the pricing of 3,358,602 shares of common stock at $26.50 per share, with expected gross proceeds of approximately $100 million, reflecting strong market confidence in its biotech products.
- Investor Participation: The offering attracted participation from notable investors including Gilead Sciences and several investment firms, indicating recognition of Assembly Bio's potential in treating viral and liver diseases, which may provide robust funding support for future R&D.
- Use of Proceeds: The company plans to utilize the net proceeds for clinical development and general corporate purposes, which will accelerate the clinical trial processes of its pipeline candidates, thereby enhancing its position in the competitive biopharmaceutical market.
- Underwriter Arrangement: Guggenheim Securities and UBS Investment Bank are acting as joint book-running managers for the offering, ensuring professionalism and efficiency in the financing process, which further boosts investor confidence in the transaction.
See More
Assembly Biosciences Reports Strong FY Results Exceeding Expectations
- Strong Earnings Report: Assembly Biosciences reported a FY GAAP EPS of -$0.55, beating expectations by $3.01, indicating a significant improvement in financial performance.
- Significant Revenue Growth: The company achieved revenue of $72.3 million, a 153.5% year-over-year increase, surpassing market expectations by $35.02 million, reflecting strong demand for its products and services.
- Robust Cash Position: As of December 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $248.1 million, an increase from $232.6 million as of September 30, 2025, demonstrating financial health.
- Sufficient Funding: The company’s cash reserves are projected to fund operations into 2028, enhancing investor confidence in its long-term growth prospects.
See More
Gilead Licenses Assembly Bio's HSV Programs, Secures $35 Million Investment
- Exclusive Licensing Agreement: Gilead Sciences has exercised its option to exclusively license Assembly Bio's HSV inhibitor programs, including ABI-1179 and ABI-5366, marking the first advancement under their R&D collaboration and potentially benefiting over four million patients.
- Positive Clinical Data: Interim Phase 1b data for ABI-5366 and ABI-1179 demonstrated antiviral activity with a significant reduction in virus-positive lesions, indicating promising clinical prospects for treating recurrent genital herpes.
- Clear Financial Terms: Under the 2023 collaboration agreement, Assembly Bio will receive a $35 million upfront payment and is eligible for up to $330 million in regulatory and commercial milestone payments, reflecting Gilead's commitment to the project's future potential.
- Significant Market Opportunity: Given that no new therapies have been approved for HSV in over 25 years, Gilead's initiative not only fills a market gap but also enhances its competitive position in the antiviral drug market by improving patient quality of life.
See More
Gilead Secures Exclusive License for Assembly Bio's HSV Programs, Receives $35M Payment
- Exclusive Licensing Agreement: Gilead Sciences has exercised its option to exclusively license Assembly Biosciences' HSV programs, gaining rights to clinical development and commercialization of ABI-1179 and ABI-5366, marking a strategic expansion in the antiviral sector.
- Financial Injection: Assembly Bio will receive a $35 million payment from Gilead's exercise of the license, which not only strengthens its financial position but also provides funding for future research and development efforts.
- Potential Earnings: Assembly Bio remains eligible for up to $330 million in regulatory and commercial milestone payments, along with tiered royalties on net sales, significantly enhancing its future revenue potential.
- Market Impact: Gilead's acquisition bolsters its market position in reproductive health, with expectations to accelerate the clinical development of related products, thereby securing a more advantageous stance in the competitive antiviral drug market.
See More
Assembly Biosciences Prices Underwritten Offering at $2.65 per Share
- Offering Size: Assembly Biosciences has priced its offering of 3,358,602 shares of common stock at $2.65 per share, aiming to raise approximately $100 million to support the development of its pipeline candidates and for general corporate purposes.
- Pre-Funded Warrants: The company is also offering certain investors pre-funded warrants to purchase up to 415,000 shares at an exercise price of $0.001 per share, which enhances investor flexibility and participation.
- Underwriter Option: Assembly has granted underwriters a 30-day option to purchase an additional 566,040 shares at the same offering price, potentially providing additional financial support and enhancing the company's liquidity.
- Closing Date: The offering is expected to close on or before May 26, 2026, marking a proactive approach in the capital markets to secure funding for future research and operational needs.
See More
Assembly Biosciences Prices 3.36M Share Offering at $26.50
- Offering Size: Assembly Biosciences announced an underwritten offering of approximately 3.36 million common shares at $26.50 per share, expecting to generate about $100 million in gross proceeds before expenses, thereby strengthening its financial position for future growth.
- Investor Participation: The offering attracted participation from both new and existing investors, including Gilead Sciences and Commodore Capital, reflecting market confidence in the company's potential and further solidifying its investor base in the biopharmaceutical sector.
- Additional Option: The company granted underwriters a 30-day option to purchase up to an additional 566,040 shares, enhancing the offering's flexibility and market responsiveness, which could potentially increase the total financing amount.
- Use of Proceeds: The net proceeds from the offering will be used to fund clinical development of pipeline candidates and for general corporate purposes, indicating the company's commitment to advancing its R&D efforts and optimizing resource allocation for long-term growth.
See More
Assembly Biosciences Prices $100 Million Underwritten Offering
- Offering Size: Assembly Biosciences announced the pricing of 3,358,602 shares of common stock at $26.50 per share, with expected gross proceeds of approximately $100 million, reflecting strong market confidence in its biotech products.
- Investor Participation: The offering attracted participation from notable investors including Gilead Sciences and several investment firms, indicating recognition of Assembly Bio's potential in treating viral and liver diseases, which may provide robust funding support for future R&D.
- Use of Proceeds: The company plans to utilize the net proceeds for clinical development and general corporate purposes, which will accelerate the clinical trial processes of its pipeline candidates, thereby enhancing its position in the competitive biopharmaceutical market.
- Underwriter Arrangement: Guggenheim Securities and UBS Investment Bank are acting as joint book-running managers for the offering, ensuring professionalism and efficiency in the financing process, which further boosts investor confidence in the transaction.
See More
Assembly Biosciences Reports Strong FY Results Exceeding Expectations
- Strong Earnings Report: Assembly Biosciences reported a FY GAAP EPS of -$0.55, beating expectations by $3.01, indicating a significant improvement in financial performance.
- Significant Revenue Growth: The company achieved revenue of $72.3 million, a 153.5% year-over-year increase, surpassing market expectations by $35.02 million, reflecting strong demand for its products and services.
- Robust Cash Position: As of December 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $248.1 million, an increase from $232.6 million as of September 30, 2025, demonstrating financial health.
- Sufficient Funding: The company’s cash reserves are projected to fund operations into 2028, enhancing investor confidence in its long-term growth prospects.
See More
Gilead Licenses Assembly Bio's HSV Programs, Secures $35 Million Investment
- Exclusive Licensing Agreement: Gilead Sciences has exercised its option to exclusively license Assembly Bio's HSV inhibitor programs, including ABI-1179 and ABI-5366, marking the first advancement under their R&D collaboration and potentially benefiting over four million patients.
- Positive Clinical Data: Interim Phase 1b data for ABI-5366 and ABI-1179 demonstrated antiviral activity with a significant reduction in virus-positive lesions, indicating promising clinical prospects for treating recurrent genital herpes.
- Clear Financial Terms: Under the 2023 collaboration agreement, Assembly Bio will receive a $35 million upfront payment and is eligible for up to $330 million in regulatory and commercial milestone payments, reflecting Gilead's commitment to the project's future potential.
- Significant Market Opportunity: Given that no new therapies have been approved for HSV in over 25 years, Gilead's initiative not only fills a market gap but also enhances its competitive position in the antiviral drug market by improving patient quality of life.
See More
Gilead Secures Exclusive License for Assembly Bio's HSV Programs, Receives $35M Payment
- Exclusive Licensing Agreement: Gilead Sciences has exercised its option to exclusively license Assembly Biosciences' HSV programs, gaining rights to clinical development and commercialization of ABI-1179 and ABI-5366, marking a strategic expansion in the antiviral sector.
- Financial Injection: Assembly Bio will receive a $35 million payment from Gilead's exercise of the license, which not only strengthens its financial position but also provides funding for future research and development efforts.
- Potential Earnings: Assembly Bio remains eligible for up to $330 million in regulatory and commercial milestone payments, along with tiered royalties on net sales, significantly enhancing its future revenue potential.
- Market Impact: Gilead's acquisition bolsters its market position in reproductive health, with expectations to accelerate the clinical development of related products, thereby securing a more advantageous stance in the competitive antiviral drug market.
See More
